Cyclerion Therapeutics, INC Form 4 insider transactions

Cyclerion Therapeutics announces progress on its merger with Korsana Biosciences, highlighting potential advancements in neurodegenerative disease therapies.

Cyclerion Therapeutics announces progress on its merger with Korsana Biosciences, detailing forward-looking statements and regulatory filings.

Cyclerion Therapeutics and Korsana Biosciences have entered into a merger agreement, aiming to combine their operations and advance drug development pipelines.

Korsana Biosciences announces key executive and board appointments to advance its lead Alzheimer's candidate, KRSA-028, and prepare for its merger with Cyclerion Therapeutics.

Peter M Hecht, a Director and 10% owner of Cyclerion Therapeutics, Inc., reported multiple transactions in common stock on July 16, 2026.

Korsana Biosciences announces a reverse merger with Cyclerion Therapeutics, aiming to advance its novel Alzheimer's therapy, KRSA-028, with a $380M financing.

Cyclerion Therapeutics announced a definitive merger agreement with privately-held Korsana Biosciences, coupled with a $380 million private placement, to advance Korsana's neurodegenerative disease pipeline.

Cyclerion Therapeutics' Chief Financial Officer, Rhonda M. Chicko, was granted an option to purchase 25,000 shares of common stock.

Director Peter Hecht purchased 181,818 shares of Cyclerion Therapeutics in a private placement for approximately $500,000.

Director Michael J. Higgins purchased 9,090 shares of Cyclerion Therapeutics (CYCN) common stock in a private placement transaction.

Slate Path Capital LP sold 357,880 shares of Cyclerion Therapeutics common stock at a price of $1.5511 per share on November 21, 2024.

Regina Graul, President and CEO of Cyclerion Therapeutics, was granted options to purchase 55,849 shares of the company's common stock.